WO2010066687A3 - Stabalized statin-comprising compositions - Google Patents

Stabalized statin-comprising compositions Download PDF

Info

Publication number
WO2010066687A3
WO2010066687A3 PCT/EP2009/066546 EP2009066546W WO2010066687A3 WO 2010066687 A3 WO2010066687 A3 WO 2010066687A3 EP 2009066546 W EP2009066546 W EP 2009066546W WO 2010066687 A3 WO2010066687 A3 WO 2010066687A3
Authority
WO
WIPO (PCT)
Prior art keywords
statin
antioxidants
solution
stabalized
compositions
Prior art date
Application number
PCT/EP2009/066546
Other languages
French (fr)
Other versions
WO2010066687A2 (en
Inventor
De Ben Lange
Den Ronald Uil
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Publication of WO2010066687A2 publication Critical patent/WO2010066687A2/en
Publication of WO2010066687A3 publication Critical patent/WO2010066687A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

The present invention relates to a method for isolating a statin comprising spray drying a solution of said statin in an alcohol or precipitating said statin from said solution characterized in that two antioxidants are present in said solution or in that said antioxidants are added during said spray drying or during said precipitating. Furthermore there is provided a composition comprising a statin and 0.01% to 1% by weight of said composition of two antioxidants which are a carbohydrate, a carotenoid, a flavonoid, an isoflavonoid, a hydroxyacid, a phenol, a polyphenol, a sulphite salt, a terpene alcohol, thiourea, an unsaturated acid or a vitamin.
PCT/EP2009/066546 2008-12-11 2009-12-07 Stabalized statin-comprising compositions WO2010066687A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08171325.7 2008-12-11
EP08171325 2008-12-11

Publications (2)

Publication Number Publication Date
WO2010066687A2 WO2010066687A2 (en) 2010-06-17
WO2010066687A3 true WO2010066687A3 (en) 2011-03-17

Family

ID=40911098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/066546 WO2010066687A2 (en) 2008-12-11 2009-12-07 Stabalized statin-comprising compositions

Country Status (1)

Country Link
WO (1) WO2010066687A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2835364C (en) 2011-05-20 2018-10-02 Astrazeneca Uk Limited Pharmaceutical composition of rosuvastatin calcium

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US20030220343A1 (en) * 2000-10-23 2003-11-27 Sankyo Company, Limited Compositions for improving lipid content in the blood
US6673831B1 (en) * 1996-04-17 2004-01-06 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US20040126423A1 (en) * 2002-07-26 2004-07-01 Moore William D. Pharmaceutical formulation
WO2006039441A2 (en) * 2004-09-30 2006-04-13 Dr. Reddy's Laboratories Ltd. Amorphous atorvastatin calcium
US20060093591A1 (en) * 1999-04-01 2006-05-04 Farmer Sean Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
US20070202159A1 (en) * 2006-02-02 2007-08-30 Mathur Rajeev S Pharmaceutical composition comprising stabilized statin particles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673831B1 (en) * 1996-04-17 2004-01-06 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US20060093591A1 (en) * 1999-04-01 2006-05-04 Farmer Sean Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
US20030220343A1 (en) * 2000-10-23 2003-11-27 Sankyo Company, Limited Compositions for improving lipid content in the blood
US20040126423A1 (en) * 2002-07-26 2004-07-01 Moore William D. Pharmaceutical formulation
WO2006039441A2 (en) * 2004-09-30 2006-04-13 Dr. Reddy's Laboratories Ltd. Amorphous atorvastatin calcium
US20070202159A1 (en) * 2006-02-02 2007-08-30 Mathur Rajeev S Pharmaceutical composition comprising stabilized statin particles

Also Published As

Publication number Publication date
WO2010066687A2 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
NZ741022A (en) Flavonoid compositions and methods of use
WO2008087605B1 (en) Composition and method of stabilized sensitive ingredient
WO2007136762A3 (en) Production of fatty acids and derivatives thereof
WO2006079533A3 (en) Production and use of an antioxidant extract from crypthecodinium sp.
WO2008012542A3 (en) Polysaccharide derivatives of erythropoietin
WO2011142618A3 (en) Method for preparing novel processed ginseng or an extract thereof, the usually minute ginsenoside content of which is increased
WO2008126752A1 (en) Skin-lightening agent containing equol compound as active ingredient
WO2009047644A3 (en) Method of treating vitamin d insufficiency and deficiency
WO2010029302A3 (en) Compounds for treating viral infections
WO2009125964A3 (en) Composition comprising polysaccharide extracted from panax ginseng preventing and treating liver diseases
WO2012078546A3 (en) Compositions and methods for stabilizing ingredients using 2,4-pentanedione compounds
WO2010049454A3 (en) Antimicrobial composition from copepods
WO2009102845A3 (en) Food products containing omega-3 fatty acids
NO20075540L (en) Lignian-containing compositions
EP2443936A3 (en) Method for reducing the saturated fatty acid content of milk fat, products obtained and applications thereof.
BRPI0717458A8 (en) ORAL AND/OR PARENTERAL COSMETIC USE OF GLUCOSAMINE AND THE ASSOCIATION OF GLUCOSAMINE AND AT LEAST ONE POLYPHENOL COMPOUND, COSMETIC PROCESS, COMPOSITION FOR ORAL ADMINISTRATION, AND, FOOD SUPPLEMENT OR FUNCTIONAL FOOD
RU2016107746A (en) MEANS FOR THE ABSORPTION OF HYDROXYTHYROZOLES AND ITS DERIVATIVES IN VIVO, AND APPLICATION OF SUCH MEANS
WO2010062122A9 (en) Composition for preventing or treating artherosclerosis
WO2010094837A3 (en) Sugar product
WO2012033390A3 (en) Novel thiophene derivative as sglt2 inhibitor and pharmaceutical composition comprising same
WO2013007637A3 (en) Cosmetic compositions in the form of water-in-oil emulsions including a jasmonic acid derivative and a silicone surfactant
WO2008099469A1 (en) Composition and method for suppressing lipid peroxidation in erythrocytes
WO2013007447A3 (en) Edible composition
WO2010066687A3 (en) Stabalized statin-comprising compositions
WO2009121710A3 (en) Process for preparing nebivolol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09764537

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09764537

Country of ref document: EP

Kind code of ref document: A2